Drilldown: Medicines

None (1) · Bisoprolol (1) · Dexmethylphenidate (1) · Nebivolol (1) · Sildenafil (1)

Bystolic (1) · Focalin, Focalin XR (1) · Viagra, Revatio (1) · Vraylar (1) · Zebeta (1)

Atypical antipsychotic (1) · Beta Blocker (2) · Cardioselective (β1) (1) · Cardioselective (β1) + vasodilator (1) · CNS stimulant (1) · D2/D3/5HT1A partial agonist (1) · NDRI (1) · PDE5 Inhibitor (1) · Psychostimulant (1)

None (1) · Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) · Selective inhibitor of phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in vascular smooth muscle. In the corpus cavernosum, potentiates the NO/cGMP cascade triggered by sexual stimulation. (1) · The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1)

Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). (1) · '"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1) · '"`UNIQ--vote-0000059D-QINU`"' (1) · '"`UNIQ--vote-00000636-QINU`"', '"`UNIQ--vote-00000637-QINU`"', '"`UNIQ--vote-00000638-QINU`"' (1) · '"`UNIQ--vote-00000705-QINU`"', '"`UNIQ--vote-00000706-QINU`"' (1)

None (1) · 2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) · 5 mg daily (1) · 50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH) (1) · Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. (1)

None (1) · 1.5 mg, 3 mg, 4.5 mg, 6 mg capsules (1) · 2.5, 5, 10, 20 mg tabs (1) · 25, 50, 100 mg tabs (Viagra); 20 mg tabs and 10 mg/mL oral suspension (Revatio) (1) · 5, 10 mg tabs (1)

None (1) · 100 mg/d (ED); 20 mg TID (PAH) (1) · 20 mg/d (1) · 40 mg/d (1) · 6 mg/d (psychosis/mania); 3 mg/d (depression adjunct) (1)

IV (Revatio) (1) · Oral (5)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

24 h (2) · Daily dosing; active metabolites with very long half-lives (up to 1-3 weeks) (1) · IR 4–6 h; XR 8–12 h (1) · ~4 h (1)

2.2 h (IR parent); ~3 h (XR parent) (1) · 9–12 h (1) · Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses (1) · ~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) · ~4 h (1)

Adequate oral bioavailability (1) · ~12% (extensive metabolizers); ~96% (poor metabolizers) (1) · ~22–25% (1) · ~40% (1) · ~90% (low first-pass) (1)

Category B (1) · Category C (3) · Limited data (1)

Rx (1) · Rx-only in US (3) · Schedule II (1)